Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

6 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 2021-09-20 - 16 Formulaires, 16 Groupes Item, 68 Eléments de données, 1 Langue
Groupes Item: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 1-3

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 4-6

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 7-9

16 Groupes Item 68 Eléments de données

Baseline

13 Groupes Item 77 Eléments de données

Reference

12 Groupes Item 111 Eléments de données

Breast Cancer Swedish National Quality Registry - Report

- 2018-02-07 - 1 Formulaire, 7 Groupes Item, 43 Eléments de données, 2 Langues
Groupes Item: National Quality Register for Breast Cancer, Report, Hospital, Diagnosis, Menstruation Status, TNM Classification, Care planning, Pathology from intervention / needle core biopsy
Description of registry: The aim of the National Quality Registry for Breast Cancer is to: -in an objective and standardised manner, monitor the continuum of care from diagnosis to any recurrence and death -enable the identification of regional differences -collectively relate to current guidelines and quality targets set by specialist associations and the National Board of Health and Welfare -facilitate research and developments in breast cancer. Report Source: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/dokument/ Facts Owner: Kerstin Sandelin surgeon, Karolinska University Hospital, Solna kerstin.sandelin@sll.se

UKHD - Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Verlaufsangaben

- 2022-03-09 - 10 Formulaires, 3 Groupes Item, 38 Eléments de données, 1 Langue
Groupes Item: Verlaufsangaben, Präoperative Vorbereitung - Checkliste, OP und Verlauf
Routinedokumentation der Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Multimodale Brustdiagnostik. Sektionsleiter Senologie: Prof. Dr. med. Jörg Heil, MHBA

Empfehlung des postoperativen Tumorboards

1 Groupe Item 26 Eléments de données

Poststationäre Ergänzungen

1 Groupe Item 2 Eléments de données

Pathologie

3 Groupes Item 121 Eléments de données

Procedere

1 Groupe Item 27 Eléments de données

Prätherapeutische und präoperative Konferenz(en)

5 Groupes Item 46 Eléments de données

Allgemeines: Personalien, Diagnose, Therapie und Anamnese

3 Groupes Item 43 Eléments de données

TNM Staging GSK study Prostatic neoplasms NCT00883909

- 2017-11-26 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue
Groupes Item: Administrative data, TNM Staging History
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Tumor Documentation University Hospital Cologne

- 2017-03-13 - 1 Formulaire, 11 Groupes Item, 69 Eléments de données, 1 Langue
Groupes Item: Tumor Documentation, Status at Initial Diagnosis, Location, Recurrent Tumor, Pathology, Lymph nodes, Procedere, Operative Surgical Procedures, Therapeutic Radiology, Chemotherapy, Case Management, Palliative medicine, oncologic psychotherapy
Study Description: Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: Tumordokumentation CIO

German Hodgkin Study Group Study HD16/HD17/HD18 Staging G6E DRKS00003457 DRKS00003455 - Deutsche Hodgkin Studiengruppe: G6E Erhebungsbogen

- 2018-11-01 - 1 Formulaire, 9 Groupes Item, 108 Eléments de données, 1 Langue
Groupes Item: Form Header, Nodal involvement, Organ involvement, Examinations, MRI instead of CT, Other examinations, Risk factors, Ann-Arbor Staging, Comments
HD16 NCT Nr.: NCT00736320 HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET. This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS). HD17 NCT Nr.: NCT01356680 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma.This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS). HD18 NCT Nr.: NCT00515554 HD18 for Advanced Stages in Hodgkins Lymphoma. This study is designed to test: in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS. Permission granted by: Andreas Engert, M.D. Chairman, German Hodgkin Study Group Professor for Internal Medicine Hematology & Oncology University Hospital of Cologne Department of Internal Medicine I Kerpener Str. 62 D-50924 Köln Phone: +49-221-478-5933/5966 Fax: +49-221-478-3778 a.engert@uni-koeln.de

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial